The Prognostic Value of Baseline Lymphocyte, Neutrophil, and Monocyte Counts in Locally Advanced Cervical Carcinoma Treated with Radiation

Table 3

Univariate analysis of potential factors associated with OS and PFS.

Variable	Overall survival		Progression-free survival
	Hazard ratio [95% CI]		Hazard ratio [95% CI]
Age (years)	1.00 [0.99–1.02]	0.611	1.01 [0.99–1.02]	0.376
Race
White	Reference		Reference
Black	0.79 [0.19–3.29]	0.749	0.94 [0.30–3.01]	0.920
Other	0.93 [0.22–3.97]	0.927	1.07 [0.33–3.5]	0.912
BMI (kg/m^2)	0.98 [0.94–1.01]	0.149	0.99 [0.96–1.01]	0.31
Smoker
Smoker	Reference		Reference
Nonsmoker	1.17 [0.74–1.88]	0.503	1.04 [0.70–1.56]	0.851
Histology
Squamous	Reference		Reference
Adenocarcinoma	0.37 [0.05–2.71]	0.330	0.57 [0.80–4.14]	0.582
Adenosquamous	0.42 [0.05–3.38]	0.418	0.80 [0.10–6.11]	0.827
Stage
IB2	Reference		Reference
IIA	0.31 [0.10–0.91]	0.034	0.35 [0.15–0.78]	0.10
IIB	0.31 [0.09–1.05]	0.061	0.32 [0.13–0.79]	0.14
IIIA	0.50 [0.20–1.25]	0.139	0.35 [0.16–0.73]	0.006
IIIB	1.39 [0.46–4.17]	0.561	0.47 [0.15–1.48]	0.197
IVA	1.14 [0.52–2.57]	0.761	0.85 [0.45–1.63]	0.631
Treatment
RT alone	Reference		Reference
CRT	2.33 [1.06–5.12]	0.036	2.45 [1.26–4.74]	0.008
Circulating neutrophil count	1.11 [1.05–1.17]	<0.001	1.12 [1.03–1.19]	<0.001
Circulating lymphocyte count	0.80 [0.60–1.06]	0.119	0.83 [0.65–1.07]	0.147
Circulating monocyte count	2.45 [1.39–4.31]	0.002	2.15 [1.23–3.75]	0.007